OpGen Q1 revenue $0.91M (up 94% YoY), FDA UTI submission, Fisher deal, cash burn guidance

CapForce Inc.

2023-Q1 EPS reported -$1.25 revenue$913,444

Q1 2023 revenue $0.91M, up 94% YoY ($0.47M) and 26% QoQ ($0.72M).
Submitted De Novo FDA application for Unyvero UTI panel; FDA confirmed complete review initiated.
Non-exclusive distribution agreement with Fisher Healthcare for Unyvero A50 platform and tests.
Cash $7.0M at Mar 31; 2023 guidance: revenue $4-5M, net cash consumption $4.5-5M/quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CapForce Inc. reported first quarter 2023 results: revenue $0.91 million. Guidance reaffirmed.

Period: first quarter 2023
Revenue: $0.91 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the first quarter of 2023 was approximately $0.91 million

View on SEC.gov

Browse all earnings releases →

CapForce Inc. filing history →

Source: SEC EDGAR

accession 0001079973-23-000728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.